

CORRECTIONS

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B.

2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines



J Am Coll Cardiol. 2019;74:1376–414.

1. Page 1376, in the author list, and page 1406, in Appendix 2, “Author Relationships With Industry and Other Entities (Relevant)...” Dr. Himmelfarb’s name has been updated to read, “Cheryl Dennison Himmelfarb.”
2. Page 1378, “Top 10 Take-Home Messages for the Primary Prevention of Cardiovascular Disease”. Take-Home Message 4. The first sentence read, “All adults should consume a healthy diet that... minimizes the intake of *trans* fats, processed meats...” It has been updated to read, “All adults should consume a healthy diet that... minimizes the intake of *trans* fats, red meat and processed red meats...”
3. Page 1379, “1.1. Methodology and Evidence Review,” second column, third paragraph. The second sentence read, “Avalere Health commissioned the Pacific Northwest Evidence-based Practice Center at Oregon Health and Science University to perform rapid systematic evidence reviews for 5 of the key topics: aspirin use, T2DM, nutrition and diet, obesity and weight loss, and tobacco use.” It has been updated to read, “As document manager, Avalere facilitated the deliberations of the Writing Committee and led the modified Delphi process for establishing the Class of Recommendation and the Level of Evidence.”
4. Page 1392, Table 8, “Highlights of Recommended Behavioral and Pharmacotherapy Tobacco Treatment Modalities for Prescribers”. The following changes have been made:
 - Under the heading “NRT,” in the row beginning “Patch,” third column, the entry read, “Starting dose: 21 mg for >10 CPD...” It has been updated to read, “Starting dose: 21 mg for ≥10 CPD...”
 - Under the heading “NRT,” in the row beginning “Nasal spray,” third column, the entry read, “Starting dose: 1-2 doses/h (1 dose=2 sprays)...” It has been updated to read, “Starting dose: 1-2 doses/h (1 dose=1 spray each nostril)...”
 - Under the heading “NRT,” in the row beginning “Oral inhaler,” second column, the entry read, “10, 10-mg cartridge” It has been updated to read, “10-mg cartridge”.
 - Under the heading “NRT,” in the row beginning “Oral inhaler,” third column, the entry read, “Starting dose...maximum 6-16 cartridges/d; taper over 3-6 mo.§” It has been updated to read, “Starting dose...maximum 16 cartridges/d.”
 - The symbol after the heading “Other” has been updated from “||” to “§”.
 - In the legend, the fourth paragraph (“§See Rx for Change for greater detail: <http://rxforchange.ucsf.edu> (S4.5-10).”) has been deleted.
 - In the legend, the paragraph beginning “||The FDA has issued...” has been updated to read, “§The FDA has issued...”
5. Page 1395, References section, first column. The heading “2. OVERARCHING RECOMMENDATIONS FOR ASCVD PREVENTION EFFORTS” has been added.
6. Page 1397, References section, first column. The heading “3. LIFESTYLE FACTORS AFFECTING CARDIOVASCULAR RISK” has been added.
7. Page 1398, References section, first column. The heading “4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK” has been added.
8. Page 1401, References section, first column. Reference S4.5-10 read, “University of Southern California. Rx for change: clinician-assisted tobacco cessation. Available at: <http://rxforchange.ucsf.edu/>. Accessed January 30, 2019.” It has been deleted.

9. Page 1407, Appendix 2, “Author Relationships With Industry and Other Entities (Relevant)...” Dr. Ziaieian’s employment has been updated to read, “University of California at Los Angeles/U.S. Department of Veterans Affairs Greater Los Angeles Healthcare System, David Geffen School of Medicine-Assistant Professor, Division of Cardiology.”

The online version has been corrected to reflect these changes.

<https://doi.org/10.1016/j.jacc.2019.07.010>

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaieian B.

2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines



J Am Coll Cardiol. 2019;74:e177-232.

1. Page e177, author list, and page e224, Appendix 2, “Author Relationships With Industry and Other Entities (Relevant)...” Dr. Himmelfarb’s name has been updated to read, “Cheryl Dennison Himmelfarb.”
2. Page e179, “Top 10 Take-Home Messages for the Primary Prevention of Cardiovascular Disease,” first column, Take-Home Message 4. The first sentence read, “All adults should consume a healthy diet that... minimizes the intake of *trans* fats, processed meats...” It has been updated to read, “All adults should consume a healthy diet that... minimizes the intake of *trans* fats, red meat and processed red meats...”
3. Page e181, “1.1. Methodology and Evidence Review,” first column, second paragraph. The second sentence read, “Avalere Health commissioned the Pacific Northwest Evidence-based Practice Center at Oregon Health and Science University to perform rapid systematic evidence reviews for 5 of the key topics: aspirin use, T2DM, nutrition and diet, obesity and weight loss, and tobacco use.” It has been updated to read, “As document manager, Avalere facilitated the deliberations of the Writing Committee and led the modified Delphi process for establishing the Class of Recommendation and the Level of Evidence.”
4. Page e188, “3.1. Nutrition and Diet,” under the heading “Synopsis”. A sentence has been added to the end of the paragraph: “Processed meats are any meat preserved by smoking, curing, or salting, or additional chemical preservatives.^{S3.1-28a}”
5. Page e203, Table 8, “Highlights of Recommended Behavioral and Pharmacotherapy Tobacco Treatment Modalities for Prescribers”. The following changes have been made:
 - Under the heading “NRT,” in the row beginning “Patch,” third column, the entry read, “Starting dose: 21 mg for >10 CPD...” It has been updated to read, “Starting dose: 21 mg for ≥10 CPD...”
 - Under the heading “NRT,” in the row beginning “Nasal spray,” third column, the entry read, “Starting dose: 1-2 doses/h (1 dose=2 sprays)...” It has been updated to read, “Starting dose: 1-2 doses/h (1 dose=1 spray each nostril)....”
 - Under the heading “NRT,” in the row beginning “Oral inhaler,” second column, the entry read, “10, 10-mg cartridge.” It has been updated to read, “10-mg cartridge.”
 - Under the heading “NRT,” in the row beginning “Oral inhaler,” third column, the entry read, “Starting dose...maximum 6-16 cartridges/d; taper over 3-6 mo.§” It has been updated to read, “Starting dose...maximum 16 cartridges/d.”
 - The symbol after the heading “Other” has been updated from “||” to “§”.
 - In the legend, the fourth paragraph (“§See Rx for Change for greater detail: <http://rxforchange.ucsf.edu> (S4.5-35).”) has been deleted.
 - In the legend, the paragraph beginning “||The FDA has issued....” has been updated to read, “§The FDA has issued....”
6. Page e208, References section, first column. The heading “2. OVERARCHING RECOMMENDATIONS FOR ASCVD PREVENTION EFFORTS” has been added.